Krystal Biotech 3Q 2026: Revenue $127.34M, EPS $2.05— 10-Q Summary

What happened

Krystal Biotech reported third-quarter 2026 revenue of $127.34 million, up 30.2% from a year earlier, while net income fell 20.5% to $63.07 million and diluted earnings per share, or profit allocated to each share, declined 22.9% to $2.05. The company attributed growth mainly to VYJUVEK launches in Europe and Japan.

Confirmed

Global impact / market context

Revenue growth alongside lower net income and earnings per share means sales expansion did not translate into higher reported profit this quarter. For investors, the contrast makes the cost of supporting launches and the durability of overseas demand important to assessing whether revenue growth can eventually lift earnings.

Analyst inference

The article points to international VYJUVEK launches as the main source of growth, while several country-specific pricing steps remain at different stages. Pricing decisions and launch timing can influence when product sales contribute to revenue, but the article gives no forecast of their financial impact.

Analyst inference

What to watch

1. Track reported revenue and net income in subsequent quarters to see whether sales growth from VYJUVEK launches is accompanied by improving profit, rather than continued divergence. Analyst inference
2. Watch for Spain’s pricing decision expected by year-end and Italy’s planned early-2027 launch; these milestones could clarify the timing of additional country sales. Confirmed
3. Follow KB803 results expected after the final patient visit in February 2027, and whether the planned 2027 KB407 study proceeds following alignment with the FDA. Confirmed

Evidence

• Original source link unavailable